PlumX Metrics
Embed PlumX Metrics

Correction: Kwok et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers 2021, 13, 4681

Cancers, ISSN: 2072-6694, Vol: 14, Issue: 2
2022
  • 0
    Citations
  • 0
    Usage
  • 3
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Correction Description

The authors wish to make the following corrections to their paper [1]: 1. There was an error in the original publication. Page 3. “Monoallelic TP53 aberrations exert a more detrimental prognostic impact, compared to biallelic alterations.” This is incorrect. It should read: “Monoallelic TP53 alterations exert a less detrimental prognostic impact, compared to biallelic alterations.” 2. There was an error in the original publication. Page 13. “In fact, among our recently reported cohort of 20 spontaneously regressing CLL cases, three harbored TP53 mutations [2].” Reference [2] was erroneously cited. The correct reference here should be reference [1]. This sentence should read: “In fact, among our recently reported cohort of 20 spontaneously regressing CLL cases, three harbored TP53 mutations [1].” 3. There was an error in the original publication. Page 14. “in combination with existing immunomodulatory agents such as the PD-1/PD-L1 inhibitors lenalidomide and ibrutinib” This sentence should read in “in combination with existing immunomodulatory agents such as PD-1/PD-L1 inhibitors, lenalidomide and ibrutinib.” 4. In the original publication, there was a mistake in Table 1: “Döhner” was misspelt as “Doner”. The corrected Table 1 appears below. (Table Presented).

Bibliographic Details

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know